We invest in medical equipment and service development to close existing service gaps, ultimately leading the way to a better healthcare in Georgia.
Bill Huyett was appointed as a Chairmen of GHG Clinical Quality Committee on 1 September 2020. Mr. Huyett is a Director Emeritus of McKinsey and Company, Inc., where he spent 30 years serving clients in life sciences, industrial and other technology-intensive sectors on strategic and operating matters. He was formerly an Independent Chairman of GHG from September 2018 to July 2020. He serves as the lead independent director of Rockley Photonics, a NYSE-listed innovator in the application of optical semiconductors to health care. He retired in 2020 as the Chief Financial Officer of Cyclerion Therapeutics, a NASDAQ-listed biopharmaceutical innovator in Cambridge, MA. He is the co-author of a text on corporate finance: Value: Four Cornerstones of Value Creation. He currently serves on the boards of several not-for-profit institutions in life sciences, including Rockefeller University in New York and Marine Biological Laboratory in Woods Hole. Mr Huyett earned a BS in Electrical Engineering and an MBA from the University of Virginia.
Fabian Blank was appointed as a member of GHG Clinical Quality Committee on 1 September 2020. Mr. Blank is an independent investor and senior adviser in healthcare. He was formerly an Independent Director of GHG from September 2018 to July 2020. He is an early-stage investor and founder in digital health, actively involved in a portfolio of patient-centric start-ups. As an Advisory Board member, he works with a US and an Israeli start-up developing artificial intelligence and software-based solutions in the areas of diagnostics and neurological diseases, respectively. As an independent senior management and board-level adviser, he works with healthcare providers and payors, medical technology companies, and private equity firms looking at growth opportunities in healthcare including digital transformation, innovation/disruption, and M&A. Previously, Mr Blank was co-owner and CEO of a midsized rehab clinic group focused on post-acute treatment in orthopaedics and cardiology. He grew utilisation, revenues and EBITDA in a mature, highly competitive market before exiting the firm to a private equity group. Throughout his 13 years with McKinsey & Company (including at Partner level), he focused on growth topics and consumer-centric functions in mobile telecommunications and healthcare services. He spent the majority of his time in high-growth markets, working in more than 20 countries across Eastern Europe, Sub Saharan Africa, India and Southeast Asia. Mr. Blank was appointed in February 2020 as an Independent Director of Enzo Biochem, Inc., a NYSE listed Biotech and Lifesciences company focused on harnessing genetic processes to develop research tools, diagnostics and therapeutics, and provider of reference laboratory services to the medical community. Mr Blank holds a graduate degree in business management (Diploma Kaufmann) from HHL-Leipzig Graduate School of Management, with semesters at Barcelona’s ESADE and Boston University’s School of Management. He obtained his intermediate business diploma (Vordiplom) from the University of Trier.
Tim Elsigood was appointed as a member of GHG Clinical Quality Committee on 1 September 2020. Mr Elsigood has over 35 years of international healthcare management experience in over 15 countries across the world. He was formerly an Independent Director of GHG from September 2015 to July 2020. He is currently an Independent Directorof CIM Sante, one of the largest private healthcare businesses in Morocco. During 2019, he managed a healthcare facility in Abu Dhabi, on behalf of the Avivo Group; he was, until January 2019, an Independent Director of Avivo Group, based in Dubai, covering the UAE and Kuwait. The Group has a broad range of healthcare facilities and products. From 2014 to 2016, he was a Consultant Advisor to Abraaj in Egypt, Tunisia and Morocco as they expanded their healthcare operations in these countries. Prior to his role in North Africa, Mr Elsigood carried out an extensive review of a major medical diagnostics business in India, evaluating the existing business and advising potential investors on the best path to follow to expand the business and build on the existing portfolio. Before this, he was Vice President for Medsi Group, a private hospital group in Russia. Prior to this, Mr Elsigood worked in Kiev, Ukraine, where he was Chief Executive Officer of Isida Hospital, a specialist maternity and women’s hospital with a large IVF centre. He has also carried out executive healthcare roles in Romania and Greece. Initially, Mr Elsigood started his career in the UK National Health Service and after 15 years moved to the private sector in the UK. He then became Senior Vice President of Business Development in Capio AB, based in Sweden. Mr Elsigood has also served as the UK Head of Alliance Medical Ltd, the largest medical imaging company in Europe. Mr Elsigood holds an MBA with a focus on health policy and strategy.
Mike Anderson was appointed as a member of GHG Clinical Quality Committee on 1 September 2020. Dr Anderson was formerly an Independent Director of GHG from September 2015 to July 2020. He was initially appointed as a physician at West Middlesex University Hospital in 1990. He subsequently became a medical manager and joined the board of West Middlesex University NHS Trust as Medical Director in 2003. He served as a medical director at Chelsea and Westminster Hospital from 2003 to 2015, as well as continuing in his role as a physician. Dr Anderson was one of the medical directors for the North West London reconfiguration programme (Shaping a Healthier Future) and continues as a physician at Chelsea and Westminster Hospital and in private medical practice. Dr Anderson has also worked as a clinical adviser and has been chairman of hospital inspections for the Care Quality Commission. Dr Anderson is an honorary clinical senior lecturer at Imperial College of Science, Technology and Medicine and a member of the British Society of Gastroenterology and the British Association for the Study of the Liver. Dr Anderson undertook his undergraduate medical training at St Bartholomew’s Hospital in London. After general medical training and completion of his MRCP (Member of the Royal College of Physicians), he trained in gastroenterology and general medicine and completed his MD in aspects of viral hepatitis.